Tackling progressive MS

Tackling Progressive MS is a priority. ECTRIMS had a meeting on this subject and they have done a special issue on this.

Here's a list of several papers on this subject.

The International Progressive MS alliance has made these open access so please read as they may be of interest.

Progressive MS trials: Lessons learned.
Mult Scler. 2017 Oct;23(12):1583-1592.

Advancing trial design in progressive multiple sclerosis.
Fox RJ, Chataway J.Mult Scler. 2017 Oct;23(12):1573-1578.

Advancing trial design in progressive multiple sclerosis.
Miller DH, Thompson AJ.Mult Scler. 2017 Oct;23(12):1571-1572.

Barro C, Leocani L, Leppert D, Comi G, Kappos L, Kuhle J.
Fluid biomarker and electrophysiological outcome measures for progressive MS trials.Mult Scler. 2017 Oct;23(12):1600-1613.

Wolinsky JS.Patient selection for trials.Mult Scler. 2017 Oct;23(12):1636-1641

Zaratin P, Comi G, Leppert D.'Progressive MS - macro views': The need for novel clinical trial paradigms to enable drug development for progressive MS.Mult Scler. 2017 Oct;23(12):1649-1655.

Moccia M, de Stefano N, Barkhof F.Imaging outcome measures for progressive multiple sclerosis trials.Mult Scler. 2017 Oct;23(12):1614-1626.

Lassmann H.Targets of therapy in progressive MS.Mult Scler. 2017 Oct;23(12):1593-1599

Ontaneda D, Cohen JA, Amato MP.Clinical outcome measures for progressive MS trials.Mult Scler. 2017 Oct;23(12):1627-1635.

First thing: What have I done to not get an invite :-(?

Maybe I am too frank!

What do these papers say:

There are three broad areas: systemic inflammation, compartmentalized inflammation and non-inflammatory neurodegeneration. They say "anti-inflammatory treatments are unlikely to be beneficial in this (progressive) stage of the disease, but neuroprotective and repair-inducing strategies may still be effective."

So maybe that's the problem. DrK would say "nonsense, wake-up and smell the roses people".  

They will say "this is why we won't support #ChariotMS, because it won't work". 

I say "Is there ambition to try and make a difference?" We think we need to deal with inflammation that occurs throughout MS, and likewise we need to protect and repair throughout MS
Last Years Burning Debate @ ECTRIMS
Gave us a Flavour of What Some of our Colleagues 
Think about Trials in Advance MS

If you are sensitive to views, that you don't want to hear 
Don't listen or press the triangle!

What do you think?